Methoxpropamine
![]() | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H23NO2 |
| Molar mass | 261.365 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Methoxpropamine (MXPr, 2-Oxo-3'-methoxy-PCPr) is a dissociative anesthetic drug of the arylcyclohexylamine class and NMDA receptor antagonist[1] that is closely related to substances such as methoxetamine and PCPr.[2] It has been sold online as a designer drug, first being identified in Denmark in October 2019,[3] and is illegal in Finland.[4]
See also
References
- ^ Irie T, Yamazaki D, Kikura-Hanajiri R (July 2021). "A potential of methoxpropamine to be a widespread recreational drug: it blocks NMDA receptors and inhibits NMDA receptor-mediated synaptic transmission in a brain preparation of mice". Forensic Toxicology. 39 (2): 474–80. doi:10.1007/s11419-021-00571-0. S2CID 232273277.
- ^ Goncalves R, Castaing N, Richeval C, Ducint D, Titier K, Morvan E, et al. (April 2022). "Methoxpropamine (MXPr) in powder, urine and hair samples: Analytical characterization and metabolite identification of a new threat". Forensic Science International. 333: 111215. doi:10.1016/j.forsciint.2022.111215. PMID 35151938. S2CID 246685658.
- ^ "EU Early Warning System Situation Report. Situation report 1" (PDF). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). June 2020.
- ^ "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista" [Government decree on psychoactive substances banned from the consumer market]. Finlex Data Bank (in Finnish). Finnish Ministry of Justice.
| |||||||||||||||||||||||||||||||||||||
| σ1 |
|
|---|---|
| σ2 |
|
| Unsorted |
|
See also: Receptor/signaling modulators | |
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.
